2754 First interim analysis of OTILIA, a large German non-interventional study evaluating front-line bevacizumab (BEV)-containing therapy in patients with ovarian cancer (OC). (September 2015) - Mustea, A.; Oskay-Oezcelik, G.; Wimberger, P.; Reichert, D.; Forstbauer, H.; Keller, M.; Frank, M.; Klawitter, S.; Kiewitz, C.; Mueller, M.; Sehouli, J.